Epigenetic Inactivation of Notch-Hes Pathway in Human B-Cell Acute Lymphoblastic Leukemia

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Kuang, Shao Qing ^a,b   Fang, Zhihong ^a   Zweidler McKay, Patrick A ^a   Yang, Hui ^a   Wei, Yue ^a   Gonzalez Cervantes, Emilio A ^a   Boumber, Yanis ^a   Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; JAGGED1; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HES 2; TRANSCRIPTION FACTOR HES 4; TRANSCRIPTION FACTOR HES 5; UNCLASSIFIED DRUG;

ACETYLATION; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; DNA MODIFICATION; DNA SEQUENCE; EPIGENETICS; GENE; GENE INACTIVATION; GENE SILENCING; HES2 GENE; HES4 GENE; HES5 GENE; HUMAN; HUMAN CELL; JAG1 GENE; LEUKEMIA CELL LINE; NOTCH3 GENE; PROTEIN EXPRESSION; PYROSEQUENCING; T LYMPHOCYTE;

APOPTOSIS; AZACITIDINE; B-LYMPHOCYTES; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOOD CELLS; BONE MARROW; CALCIUM-BINDING PROTEINS; CELL LINE, TUMOR; CELL LINEAGE; CELL PROLIFERATION; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENE SILENCING; HEMATOPOIESIS; HISTONES; HUMANS; HYDROXAMIC ACIDS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, B-CELL; MEMBRANE PROTEINS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, NOTCH; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC;

EID: 84876875856     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061807     Document Type: Article

References (25)

1. Dotto GP, (2008) Notch tumor suppressor function. Oncogene 27: 5115-5123.
2. Jundt F, Schwarzer R, Dorken B, (2008) Notch signaling in leukemias and lymphomas. Curr Mol Med 8: 51-59.
3. Singh N, Phillips RA, Iscove NN, Egan SE, (2000) Expression of notch receptors, notch ligands, and fringe genes in hematopoiesis. Exp Hematol 28: 527-534.
4. Choi JH, Park JT, Davidson B, Morin PJ, Shih Ie M, et al. (2008) Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res 68: 5716-5723.
5. Katoh M, Katoh M, (2007) Integrative genomic analyses on HES/HEY family: Notch-independent HES1, HES3 transcription in undifferentiated ES cells, and Notch-dependent HES1, HES5, HEY1, HEY2, HEYL transcription in fetal tissues, adult tissues, or cancer. Int J Oncol 31: 461-466.
6. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, et al. (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271.
7. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, et al. (1991) TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66: 649-661.
8. Walter K, Bonifer C, Tagoh H, (2008) Stem cell-specific epigenetic priming and B cell-specific transcriptional activation at the mouse Cd19 locus. Blood 112: 1673-1682.
9. He Y, Pear WS, (2003) Notch signalling in B cells. Semin Cell Dev Biol 14: 135-142.
10. Leong KG, Karsan A, (2006) Recent insights into the role of Notch signaling in tumorigenesis. Blood 107: 2223-2233.
11. Aster JC, Pear WS, Blacklow SC, (2008) Notch signaling in leukemia. Annu Rev Pathol 3: 587-613.
12. Talora C, Cialfi S, Oliviero C, Palermo R, Pascucci M, et al. (2006) Cross talk among Notch3, pre-TCR, and Tal1 in T-cell development and leukemogenesis. Blood 107: 3313-3320.
13. Zweidler-McKay PA, (2008) Notch signaling in pediatric malignancies. Curr Oncol Rep 10: 459-468.
14. Zweidler-McKay PA, He Y, Xu L, Rodriguez CG, Karnell FG, et al. (2005) Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood 106: 3898-3906.
15. Ivascu C, Wasserkort R, Lesche R, Dong J, Stein H, et al. (2007) DNA methylation profiling of transcription factor genes in normal lymphocyte development and lymphomas. Int J Biochem Cell Biol 39: 1523-1538.
16. Garcia-Manero G, Yang H, Kuang SQ, O'Brien S, Thomas D, et al. (2009) Epigenetics of acute lymphocytic leukemia. Semin Hematol 46: 24-32.
17. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, et al. (2008) Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 40: 741-750.
18. Kapoor-Vazirani P, Kagey JD, Powell DR, Vertino PM, (2008) Role of hMOF-dependent histone H4 lysine 16 acetylation in the maintenance of TMS1/ASC gene activity. Cancer Res 68: 6810-6821.
19. Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, et al. (2008) Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 22: 1529-1538.
20. Shu J, Jelinek J, Chang H, Shen L, Qin T, et al. (2006) Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res 66: 5077-5084.
21. Wang Z, Miura N, Bonelli A, Mole P, Carlesso N, et al. (2002) Receptor tyrosine kinase, EphB4 (HTK), accelerates differentiation of select human hematopoietic cells. Blood 99: 2740-2747.
22. Kuang SQ, Ling X, Sanchez-Gonzalez B, Yang H, Andreeff M, et al. (2007) Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation. Oncogene 26: 1439-1448.
23. Roman-Gomez J, Jimenez-Velasco A, Barrios M, Prosper F, Heiniger A, et al. (2007) Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes. Leuk Lymphoma 48: 1269-1282.
24. Yendamuri S, Trapasso F, Ferracin M, Cesari R, Sevignani C, et al. (2007) Tumor suppressor functions of ARLTS1 in lung cancers. Cancer Res 67: 7738-7745.
25. Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, et al. (2011) A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 473: 230-233.